Fractyl Health announced today that it activated the 10th clinical site in its pivotal REVITA-T2Di trial in the U.S. and Europe. Lexington, Mass.-based Fractyl’s trial is enrolling patients with type 2 diabetes who are currently on insulin therapy at sites in New Jersey, Louisiana, Texas, Massachusetts and New York to add to the initial U.S. site […]
Fractyl Labs said yesterday that a study of its Revita duodenal mucosal resurfacing system reported significant changes in blood sugar in type 2 diabetes patients, similar to those seen with bariatric surgery procedures. Data from the study was presented at the 3rd World Congress on Interventional Therapies for Type 2 Diabetes in London this week, Waltham, Mass.-based […]
Fractyl Labs said today it enrolled the 1st patients in a trial of its Revita duodenal mucosal resurfacing system designed to treat the digestive causes of insulin resistance in patients with type 2 diabetes. The Revita device is designed to ablate the duodenum (the first part of the intestine) in order to alter glucose metabolism. […]
Massachusetts medical device maker Fractyl announced this week that it raised $40 million in support of its ablation-based approach to type 2 diabetes, which looks promising in early studies.